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Abstract: Choroidal endothelial cells supply oxygen and nutrients to retinal pigment epithelial (RPE)
cells and photoreceptors, recycle metabolites, and dispose of metabolic waste through the choroidal
blood circulation. Death of the endothelial cells of the choroid may cause abnormal deposits including
unesterified and esterified cholesterol beneath RPE cells and within Bruch’s membrane that contribute
to the progression of age-related macular degeneration (AMD), the most prevalent cause of blindness
in older people. Translocator protein (TSPO) is a cholesterol-binding protein that is involved in
mitochondrial cholesterol transport and other cellular functions. We have investigated the role of
TSPO in choroidal endothelial cells. Immunocytochemistry showed that TSPO was localized to the
mitochondria of choroidal endothelial cells. Choroidal endothelial cells exposed to TSPO ligands
(Etifoxine or XBD-173) had significantly increased cholesterol efflux, higher expression of cholesterol
homeostasis genes (LXRα, CYP27A1, CYP46A1, ABCA1 and ABCG1), and reduced biosynthesis of
cholesterol and phospholipids from [14C]acetate, when compared to untreated controls. Treatment
with TSPO ligands also resulted in reduced production of reactive oxygen species (ROS), increased
antioxidant capacity, and reduced release of pro-inflammatory cytokines (IL-1β, IL-6, TNF-α and
VEGF) induced by oxidized LDL. These data suggest TSPO ligands may offer promise for the
treatment of AMD.
Keywords: TSPO; cholesterol efflux; oxidative stress; inflammation; choroidal endothelial cells;
age-related macular degeneration
1. Introduction
Age-related macular degeneration (AMD) is the major cause of visual dysfunction in the elderly
population. Due to population ageing, it is predicted that the number of AMD patients will be
increased from 196 million in 2020 to 288 million by 2040 [1]. AMD is classed as two types: the dry
form with geographic atrophy and the wet form with neovascularization. Pathological characterization
of retinas from AMD patients demonstrated that photoreceptors, retinal pigment epithelial (RPE) cells
and choroidal endothelial cells were affected and had degenerated [2]. Choroidal endothelial cells
were markedly lost in AMD patients, the loss occurring earlier than that of RPE cells [2]. Another study
also suggested early degeneration of choroidal endothelial cells in dry AMD, showing significantly
decreased expression of endothelium-associated genes in RPE/choroid [3]. The choriocapillaris (CC)
Int. J. Mol. Sci. 2018, 19, 3740; doi:10.3390/ijms19123740 www.mdpi.com/journal/ijms
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provides oxygen and nutrients for RPE cells and for photoreceptors and clears metabolic waste from
these cells via the systemic circulation [4]. Previous studies showed that CC density was significant
lower in AMD patients compared to control groups of the same age [2] and that loss of CC was
positively correlated with drusen formation in early AMD [5]. An early study in rabbits demonstrated
that RPE cells were required for modulating CC structure and function [6]. However, analysis of AMD
patient samples showed that, in dry AMD, the CC survived even though RPE cells were completely lost,
while in wet AMD the CC underwent marked degeneration [2,7]. Early loss of choroidal endothelial
cells and dysfunction of CC are believed to result in a defective supply of nutrients and oxygen to
RPE and photoreceptors, while more importantly compromising the recycling of metabolites and the
disposal of metabolic waste, thus leading to the formation of deposits (e.g., drusen) within Bruch’s
membrane and beneath the RPE [7].
Translocator protein (TSPO, 18 kDa) is a mitochondrial outer membrane protein, first identified as
a benzodiazepine receptor [8]. Rat TSPO can rescue the phenotype presented in Rhodobacter sphaeroides
with deletion of TSPO [9], indicating functional conservation in evolution. TSPO expresses at a high
level in a variety of tissues, particularly so in steroidogenic tissues. TSPO has five transmembrane (TM)
domains, in which TM5 holds putative cholesterol-binding sites [10]. TSPO also can bind different
types of ligands, which mediates its function. The major function of TSPO is transporting cholesterol
from the mitochondrial outer membrane (MOM) to the mitochondrial inner membrane (MIM) where
cholesterol is metabolized into pregnenolone by Cyp11A in steroid-producing cells or into oxysterols
by CYP27A1 in non-steroidogenic cells [11]. However global or conditional Tspo knock-out mouse
models have exhibited divergent phenotypes (embryonic lethal, or defect in steroidogenesis, or no
effect on steroidogenesis), possibly due to background genetic differences between strains of those KO
mice [12–16]. TSPO also has important roles to play in other cellular processes: it interacts with the
adenine nucleotide transport (ANT) and the voltage-dependent anion channel (VDAC) [17], which are
core components of the mitochondrial permeability transition pore; TSPO also regulates production of
reactive oxygen species (ROS) and mediates apoptosis [18]. TSPO expression is markedly elevated
in activated microglia in an injured brain. It is also upregulated in neurodegenerative conditions,
including amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer’s disease, Huntington’s disease
and Parkinson’s disease [19]. Both in injured and degenerating mouse retinas, TSPO expression
is also upregulated in activated microglia [20,21]. Knockdown of TSPO in BV2 microglia caused
significantly increased production of ROS and TNF-α, suggesting thatTSPO negatively regulates
microglial activation [20].
Recently we found TSPO expressed at a high level in human RPE cell line and in mouse RPE [16].
Treatment with TSPO ligands (Etifoxine, XBD173 and FGIN-1-27) caused a rise in cholesterol efflux,
decreased lipogenesis, reduced cellular phospholipids and total cholesterol, and upregulation of
cholesterol metabolism and transporter genes in RPE cells. Loss of TSPO caused increased lipid
accumulation and production of ROS and pro-inflammatory cytokines [22]. Prior to the present study,
there have been no investigations of TSPO function in choroidal endothelial cells. We found that
treatment with TSPO ligands resulted in increased cholesterol efflux to high-density lipoprotein (HDL),
reduced intracellular lipid accumulation and decreased production of ROS and secretion of cytokines
induced by oxidized low-density lipoprotein (oxLDL) in choroidal endothelial cells. Our observations
suggest that TSPO ligands have therapeutic potential for AMD.
2. Results
2.1. TSPO Ligands Increase Cholesterol Efflux and Upregulate Cholesterol Metabolism and Transporter Genes
Previous studies reported that TSPO is expressed in a wide range of cells, including umbilical vein
endothelial cells, microglia, macrophages, astrocytes, fibroblasts and RPE cells [20–28]. We investigated
TSPO expression in choroidal endothelial cells by immunostaining using a specific TSPO antibody and
found that TSPO co-localized to mitochondria with Mito Tracker, a marker of functional mitochondria
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(Figure 1A). TSPO ligands have been shown to increase cholesterol efflux from fibroblasts, macrophages
and RPE [22–24]. We determined the potential toxic effects of TSPO ligands by treating primate
choroidal endothelial cells (RF/6A) with either Etifoxine (0, 5, 7.5, 10, 15, 20 and 25 µM) or with
XBD173 (0, 5, 10, 15, 20, 25 and 30 µM) and measured cell viability after 24 h exposure using MTT
assay. RF/6A cells tolerated Etifoxine treatment at the concentrations of 5–20 µM but demonstrated a
notable decrease in cell viability at the concentration of 25 µM; similarly, RF/6A cells tolerated XBD173
treatment at doses of 5–25 µM but exhibited significantly decreased cell viability at the dose of 30 µM
(Figure 1B). Consequently, we chose Etifoxine at concentration of 20 µM and XBD173 at concentration
of 25 µM for subsequent treatments. We treated RF/6A with Etifoxine (20 µM) and XBD173 (25 µM)
for 24 h and found that exposure to both ligands caused a significant increase in cholesterol efflux
to HDL and human serum (Figure 1C). We further investigated if TSPO ligands affect expression of
genes involved in cholesterol homeostasis. After RF/6A cells were treated with TSPO ligands for 24 h,
expression of the NR1H3 gene (coded for oxysterol receptor LXRα), transporter genes (ABCA1 and
ABCG1) and metabolism genes (CYP27A1 and CYP46A1) was markedly increased in ligand-treated
RF/6A cells (Figure 2).
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Figure 1. (A) The expression and co-localisation of translocator protein (TSPO) and mitochondria in 
RF/6A cells. RF/6A cells were stained with Mito-tracker (a marker for functional mitochondria) 
following cell culture and then fixed with cold methanol. Subsequently, the slides were treated with 
anti-TSPO antibody. Images captured confocally show TSPO (Green), DAPI (Blue), mitochondria 
(Red), while the Merged image shows co-localisation of TSPO and mitochondria (630×). (B) Toxic 
effects of TSPO ligands Etifoxine and XBD173 on RF/6A cells. RF/6A cells were treated with different 
concentrations of Etifoxine for 24 h and assayed: a decline in cell viability at the concentration of 25 
μM was noted compared to the untreated controls; similarly, 30 μM XBD173 had a significant toxic 
effect compared to the control. (C) Efflux of cholesterol initiated by acceptors (APOA1, ApoE, HDL 
and HS) and incubated with TSPO ligands Etifoxine (20 μM) and XBD173 (25 μM) was studied in 
RF6A cells. The percentage of [3H]cholesterol was calculated in the media and in the cells. Data for 
(B) and (C) are shown as mean ± SD. Statistical comparisons were done using One-way ANOVA (B) 
and Two-way ANOVA (C), followed by Bonferroni test. Each experiment was performed in triplicate 
and repeated twice. NS: non-significant, * p ≤ 0.05, ** p < 0.01, *** p < 0.001 and **** p < 0.0001.  
Figure 1. (A) The expression and co-localisation of translocator protein (TSPO) and mitochondria
in RF/6A cells. RF/6 cell re stained with Mito-tracker ( marker for functional mitochondria)
following cell culture and then fixed with c ethanol. Subs quently, th slid s were treated with
anti-TSPO antibody. Images captured confocally show TSPO (Green), DAPI (Blue), mitochondria
(Red), while the Merged image shows co-localisation of TSPO and mitochondria (630×). (B) Toxic
effects of TSPO ligands Etifoxine and XBD173 on RF/6A cells. RF/6A cells were treated with different
concentrations of Etifoxine for 24 h and assayed: a decline in cell viability at the concentration of 25 µM
was noted compare to the untreated controls; similarly, 30 µM XBD173 had a significant toxic effect
compare to the co trol. (C) Efflux of chole terol initiated by cceptors (APOA1, ApoE, HDL and HS)
and incubated with TSPO ligands Etifoxine (20 µM) and XBD173 (25 µM) was studied in RF6A cells.
The percentage of [3H]cholesterol was calculated in the media and in the cells. Data for (B) and (C) are
shown as mean ± SD. Statistical comparisons were done using One-way ANOVA (B) and Two-way
ANOVA (C), followed by Bonferroni test. Each experiment was performed in triplicate and repeated
twice. NS: non-significant, * p ≤ 0.05, ** p < 0.01, *** p < 0.001 and **** p < 0.0001.
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genes in RF6A cells treated with Etifoxine (A) or XBD173 (B) were quantified by qRT-PCR. The 
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with 0.1% DMSO as a control for 24 h. All data were collected and analysed relative expression of 
β-actin and presented as mean ± SD. Statistical comparisons were done using Two-way ANOVA 
followed by Bonferroni test. NS: non-significant, * p ≤ 0.05; ** p ≤ 0.01; *** p < 0.001 and *** p ≤ 0.001. 
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Figure 2. The effects of TSPO ligands on the expression of cholesterol efflux genes and metabolism
genes in RF6A cells treated with Etifoxine (A) or XBD173 (B) were quantified by qRT-PCR. The RF/6A
cells were cultured and treated with TSPO ligands Etifoxine (20 µM) and XBD173 (25 µM) and with
0.1% DMSO as a control for 24 h. All data were collected and analysed relative expression of β-actin
and presented as mean ± SD. Statistical comparisons were done using Two-way ANOVA followed by
Bonferroni test. NS: non-significant, * p ≤ 0.05; ** p ≤ 0.01; *** p < 0.001 and *** p ≤ 0.001.
2.2. TSPO Ligands Regulate Lipogenesis in Choroidal Endothelial Cells
We examined the effect of TSPO ligands on lipogenesis in RF/6A cells by quantification of
synthesized cholesteryl, fatty acid, triglyceri es and phospholipid. We found that incorporation of
[14C]acetate into th free cholesterol pool was ig ificantly decreased by 23.6% in Etifoxine- reated
cells and by 23.9% in XBD173- reated cells, compared to control cells; incorporation of [14C]ace ate
into phospholipid was also significantly decreased by 28% in Etifoxi e-t eated cells and by 26%
in XBD173-treated cells, compared to control cells (Figure 3A,B). How ver, incorporation of
[14C]ace ate into cholesterol ester and fatty acid was not significantly changed in Etifoxine-treated
or XBD173-treated c lls wh n compared to ontrol cells; although in orporation of [14C]acet into
triglycerides was not significantly changed in Etifoxine-treated cells, it was significantly r duced in
XBD173-tr ated cells (Figure 3A,B), compared to c ntrol cells. We al o quantified tot l cholesterol and
triglyceride in control cells and in ells incubated with oxLDL, or with oxLDL and TSPO ligand.
OxLDL-tr ated cells had a 13.7% crease in cholesterol and 67% increase in triglyceride when
compared to control cells (Figure 3C,D). Total cholesterol was significantly dec eased by 38% in
Etifoxine-treated cel s and by 28% in XBD173- reated cells when compared to cells t t with oxLDL
only (Figur 3C); triglyceride was also markedly decreased by 75.1% in Etifoxine-tr ated cells and by
65% in XBD173-treated cells when compared to cells treat d sol ly with oxLDL (Figure 3D).
Lipid droplets are functiona organelles containing mainly cholesterol esters and tri lycerides.
Lipid droplets not only manage lipid storage but also mediate a variety of phy iological functions
such as protein quality control and immune response [29]. We xamin d lipid droplets in control a d
treated cells using oil red O (ORO) staining. We found that there was a significantly incr ased number
of lipid droplets in oxLDL treated cells compared to untreated control cells. Treatment with TSPO
ligand, Etifox ne or XBD173, notably decreas d the qu ntity of lipid droplets compared to cells treated
solely with oxLDL (Figure 4).
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Figure 3. TSPO ligands modified the lipid phenotypes in RF/6A cells. The effect of TSPO ligands
((A): Etifoxine, 20 µM; (B): XBD173, 25 µM) were studied on disintegrations per minute (dpm)
incorporation/mg total protein of [14C]acetate (1 µCi/mL) into free cholesterol, cholesteryl ester,
fatty acid, phospholipid and triglycerides compared with the 0.1% vehicle control. These TSPO ligands
also were applied to RF/6A cells to quantify the total cellular cholesterol (C) after the excitation of
oxLDL and with their vehicle control. Similarly, it was applied to quantify triglycerides level. All data
was represented as mean ± SD and analysed by Two-way ANOVA (A,B) and one-way ANOVA (C,D)
followed by Bonferroni test. Three independent experiments were performed and the value of statistical
were pointed as * p ≤ 0.05; ** p < 0.01, **** p < 0.0001. NS: non-significant.
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with oxLDL and with oxLDL + TSPO ligands. The oxLDL-treated cells were compared to cells 
treated with Etifoxine (20 μM) + oxLDL or with XBD173 (25 μM) + oxLDL and to vehicle-treated 
controls. The cells were then fixed with 10% formalin and stained with ORO and images were 
captured by EVOS microscopy (A). Inserts show a 2.5× magnification of the selected regions. The 
lipid droplets were eluted with 100% isopropanol and optical density (OD) at 520 nm was measured 
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were analysed using one-way ANOVA followed by Bonferroni test and presented as mean ± SD (B). 
* p ≤ 0.05, ** p < 0.01, and *** p < 0.001. 
2.3. TSPO Ligands Supress ROS Production and Increased Antioxidant Capacity 
Previous studies have demonstrated that TSPO ligands can inhibit ROS generation in different 
types of cells [30–32]. It is well documented that oxLDL can induce ROS generation and cause 
oxidative damage [33]; accordingly, we treated RF/6A cells with oxLDL to induce ROS generation. 
RF/6A cells exposed to oxLDL had a significant increase in ROS production compared to untreated 
control cells. Co-treatment with Etifoxine or XBD173 resulted in notably decreased ROS production 
(Figure 5A). As ROS generation causes imbalance of antioxidant defence, we investigated 
antioxidant gene expression in RF/6A cells. OxLDL treatment caused a significant decrease in GPX1, 
Catalase and SOD1 mRNA levels by, respectively, 26%, 45% and 25% (Figure 5B,C), compared to 
untreated control cells. Co-treatment with Etifoxine significantly increased expression of GPX1, 
Catalase and SOD1 by, respectively, 52%, 115% and 58%, compared to cells treated solely with 
oxLDL (Figure 5B); similarly, expression of GPX1, Catalase and SOD1 was also notably increased by, 
respectively, 84%, 88% and 73% in cells co-exposed to oxLDL and XBD173, compared to cells treated 
with oxLDL alone (Figure 5C). 
We also examined the effect of TSPO ligands on Catalase activity and the levels of glutathione 
(GSH) and malondialdehyde (MDA). Catalase activity was significantly decreased by 58% in 
oxLDL-treated cells when compared to untreated cells; co-treatment with Etifoxine or XBD173 led to 
notable increases in Catalase activity by 492% and 98% respectively, when compared to cells treated 
solely with oxLDL (Figure 5D). GSH, an antioxidant that protects cells from ROS-induced damage, 
was significantly decreased by 48.5% in oxLDL-treated cells when compared to untreated cells. GSH 
was markedly increased by 245% and 286%, respectively, in oxLDL-treated cells co-exposed to 
Etifoxine or XBD173 when compared to cells treated with oxLDL alone (Figure 5E). However, MDA, 
a lipid peroxidation marker, was significantly increased by 49.9% in oxLDL treated cells when 
compared to untreated controls; co-treatment with Etifoxine or XBD173 resulted in notable 
.
oxLDL and with oxLDL + TSPO ligands. The oxLDL-treated cells were compared to c lls treated
with Etifoxine (20 µM) + oxLDL or with XBD173 (25 µM) + oxLDL and to vehicle-treated controls.
The ce ls were then fixed with 10% formalin and stained with ORO and images were captured by
EVOS microscopy (A). In erts show a 2.5×magnification of the selected regions. The lipid droplets
were eluted with 100% isopropanol and optical density (OD) at 520 nm was measured u ing plate
absorbance re der. The OD was normalised with espect to total cell protein. The data were analysed
using one-way ANOVA followed by Bonferroni test and presented as m an ± SD (B). * p ≤ 0.05,
* p < 0.01, and *** p < 0.001.
2.3. TSPO Ligands Supress ROS Production and Increased Antioxidant Capacity
Previous studies have demonstrated that TSPO ligands can inhibit ROS generation in different
types of cells [30–32]. It is well documented that oxLDL can induce ROS generation and cause
oxidative damage [33]; accordingly, we treated RF/6A cells with oxLDL to induce ROS generation.
RF/6A cells exposed to oxLDL had a significant increase in ROS production compared to untreated
control cells. Co-treatment with Etifoxine or XBD173 resulted in notably decreased ROS production
(Figure 5A). As ROS generation causes imbalance of antioxidant defence, we investigated antioxidant
gene expression in RF/6A cells. OxLDL treatment caused a significant decrease in GPX1, Catalase and
SOD1 mRNA levels by, respectively, 26%, 45% and 25% (Figure 5B,C), compared to untreated control
cells. Co-treatment with Etifoxine significantly increased expression of GPX1, Catalase and SOD1 by,
respectively, 52%, 115% and 58%, compared to cells treated solely with oxLDL (Figure 5B); similarly,
expression of GPX1, Catalase and SOD1 was also notably increased by, respectively, 84%, 88% and 73%
in cells co-exposed to oxLDL and XBD173, compared to cells treated with oxLDL alone (Figure 5C).
We also examined the effect of TSPO ligands on Catalase activity and the levels of glutathione
(GSH) and malondialdehyde (MDA). Catalase activity was significantly decreased by 58% in
oxLDL-treated cells when compared to untreated cells; co-treatment with Etifoxine or XBD173 led
to notable increases in Catalase activity by 492% and 98% respectively, when compared to cells
treated solely with oxLDL (Figure 5D). GSH, an antioxidant that protects cells from ROS-induced
damage, was significantly decreased by 48.5% in oxLDL-treated cells when compared to untreated
cells. GSH was markedly increased by 245% and 286%, respectively, in oxLDL-treated cells co-exposed
to Etifoxine or XBD173 when compared to cells treated with oxLDL alone (Figure 5E). However,
MDA, a lipid peroxidation marker, was significantly increased by 49.9% in oxLDL treated cells when
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compared to untreated controls; co-treatment with Etifoxine or XBD173 resulted in notable decreases in
MDA levels by 31% and 36.29% respectively, compared to cells treated solely with oxLDL (Figure 5F).
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TNF-α, in vascular cells [34,35]. We investigated the effects of TSPO ligands on production of 
pro-inflammatory cytokines induced by oxLDL in choroidal endothelial cells. Firstly, we did 
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and VEGF genes and found expression of all examined cytokine genes was significantly increased in 
Figure 5. (A) TSPO ligands reduced the oxLDL-generated intra-cellular reactive oxygen species
(ROS) level in RF6A cells. ROS levels in cells following treatment with oxLDL were compared to
cells treated with Etifoxine (20 µM) + oxLDL, or with XBD173 (25 µM) + oxLDL for 24 h, and to
vehicle-treated control cells. The mRNA expressions of oxidative genes (GPX1, Catalase and SOD1)
were down-regulated following treatment with oxLDL compared to controls. Treatment with Etifoxine
(B) or XBD173 (C) resulted in recovery of gene expression. The protein activity of Catalse (D), GSH (E)
and MDA (F) were measured following treatment with oxLDL, with Etifoxine + oxLDL, and with
XBD173 + oxLDL. The experiments were performed three times. All data are shown as mean ± SD and
analysed using one-way ANOVA (A,D–F) and Two-way ANOVA (B,C), followed by the Bonferroni
test. * p ≤ 0.05, ** p < 0.01, *** p < 0.001 and **** p < 0.0001.
2.4. TSPO Ligands Decrease Production of Pro-Inflammatory Cytokines
OxLDL has been shown to induce secretion of pro-inflammatory cytokines, such as IL-1β
and TNF-α, in vascular cells [34,35]. We investigated the effects of TSPO ligands on production
of pro-inflammatory cytokines induced by oxLDL in choroidal endothelial cells. Firstly, we did
quantitative real-time polymerase chain reaction (qRT-PCR) to detect mRNA of TNFα, IL-1β, IL-6
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and VEGF genes and found expression of all examined cytokine genes was significantly increased
in oxLDL-treated cells when compared to untreated controls; co-treatment with Etifoxine or XBD173
notably downregulated expression of these genes (Figure 6A). We also used ELISA to measure secreted
TNF-α, IL-1β, IL-6 and VEGF and found that cells treated with oxLDL had a significant increase in
levels of these cytokines when compared to untreated cells. Similarly, co-exposure to Etifoxine or
XBD173 led to notable decrease in production of these cytokines when compared to cells treated with
oxLDL alone (Figure 6B).
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with oxLDL and TSPO ligands. (A) mRNA expression of TNF-α, IL1-β, IL-6 and VEGF relative to
β-ACTIN was measured following treatment with oxLDL and compared to that seen in cells treated
additionally with Etifoxine (20 µM) or XBD173 (25 µM) for 24 h and in vehicle-treated control cells.
(B) Following the same treatment, the protein concentrations of these genes were measured by ELISA.
Data are represented as mean ± SD and were analysed by Two-way ANOVA followed by Bonferroni
multiple comparison test. * p < 0.05, ** p < 0.01, *** p < 0.001 and **** p < 0.0001.
3. Discussion
The major clinical feature of AMD is formation of abnormal extracellular deposits known as
drusen [36]. Pathogenic nalyses of AMD patient eyes demonstrated unesterifi d and esterified
cholesterol were promine t in drusen [37], implicating abnormal cholest rol homeostasi in the
ondition. It is prop sed that excess cholesterol from RPE is recycled back o the liver for storage or
excretion through reverse chol st rol transpo t (RCT) [22,38,39]. Under physiological conditi ns RPE
cells export cholesterol to Bruch’s membrane (BrM) via ABCA1; cholesterol then crosses BrM and
enters the choroidal circulation [40]. How ver, the role of choroidal endoth lial cells i volved in the
RCT i RPE/BrM/choroid has not been studied, though th RCT in vascular endothelial cells has bee
well investigated [41]. The current study demonstrated that TSPO liga ds promot d chol sterol efflux,
d creased accumulation of oxidized LDL, increase antioxidative capacity and inhibited inflam ation
in choroidal endothelial cells.
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TSPO directly transports cholesterol from the MOM to the MIM, and TSPO ligands have been
shown to promote mitochondrial cholesterol movement [11]. However, the concept of TSPO-mediated
steroid biosynthesis faces challenge, as deletion of TSPO in mice and in MA-10 Leydig cells presented
inconsistent phenotypes [12–16,42,43]. In non-steroid-producing cells (a human macrophage cell
line), Taylor et al. reported that overexpression of TSPO increased cholesterol efflux and upregulated
cholesterol-efflux-associated genes including NR1H3, ABCA1, ABCG4 and APOE; conversely, depletion
of TSPO by siRNA knockdown caused the opposite effect. Treatment with TSPO ligands (PK11195,
FGN-1-27 and flunitrazepem) significantly increased cholesterol efflux [24]. In human RPE (ARPE-19)
cells, TSPO ligands (FGIN-1-27, XBD173 and Etifoxine) enhanced cholesterol efflux and increased
expression of cholesterol transport and metabolism genes, including NR1H3, ABCA1, ABCG1,
CYP27A1 and CYP46A1 [22]. In the present study, TSPO ligands (XBD173, 25 µM and Etifoxine,
20 µM) enhanced cholesterol efflux and upregulated expression of cholesterol-efflux-related genes
in choroidal endothelial cells (Figures 1 and 2). Our previous work also used Etifoxine and XBD173
at same concentration to treat RPE cells and found the effect of both ligands on cholesterol efflux
was TSPO-dependent [22], though early reports suggested Etifoxine also binds to GABAARs on
β subunits [44]. Interesting Costa et al. recently reported that the neurosteroidogenic ability of
both Etifoxine and XBD173 is dependent on residence time at the binding site rather than their
binding affinities [45,46]. It also worth noting that treatment with TSPO ligands resulted in decreased
lipogenesis in macrophages, RPE and choroidal endothelial cells, and that free cholesterol was
significantly lower in TSPO-ligand-treated RPE and choroidal endothelial cells when compared
to untreated controls (Refs. [22] and [24], Figure 3A,B). Cholesterol accumulation is thought to
promote inflammation in macrophages that is associated certain chronic metabolic diseases such as
atherosclerosis and obesity [47]. However, whether decreased free cholesterol in TSPO-ligand-exposed
choroidal endothelial cells will reduce intracellular cholesterol accumulation and repress inflammation
needs further investigation.
TSPO ligands have demonstrated anti-oxidative-stress and anti-inflammation capacity against
different types of stress in vitro and in vivo [48,49]. Early studies reported that TSPO ligands
(SSR180575 and Ro5-4864) protected against mitochondrial dysfunction and prevented cell death
caused by H2O2 exposure in COS7, HEK293, H9C2 and human renal proximal tubule epithelial cells
through inhibition of cytochrome c release, increase of mitochondrial membrane potential, and decrease
of caspase 3 activation [50,51]. SSR180575 also showed protection against cardiac and renal cell death
following ischemia-reperfusion (I-R) induced injury [49,50]. Similarly, TSPO ligands Ro5-4864 and
TRO40303 preserved cardiac function against oxidative damage associated with I-R injury [52–54].
Baez et al. recently demonstrated that TSPO ligand Ro5-4864 reduced production of free radicals
and helped to maintain mitochondrial function in astrocytic glioblastoma T89G cells under metabolic
damage [55]. TSPO ligand PIGAS also displayed antioxidative capacity in astrocytic C6 glioma
cells under L-buthionine-(S,R)-sulfoximine (BSO) induced toxicity, possibly through stimulation
of neurosteroid synthesis [56]. In addition, TTN, PK11195 and Ro5-4864 decreased LPS-induced
ROS production in microglia cells [20]. TSPO ligands also showed anti-inflammatory effects in
astrocytic, microglial and vascular endothelial cells. PIGAS suppressed LPS/IFNγ-induced iNOS and
COX-2 expression in astrocytic C6 glioma cells [56]. Etifoxine also decreased LPS-induced release
of IL-1β and IL-6 in rat primary astrocytes [57]. PK11195 down-regulated expression of Cox-2 in
human microglia exposed to LPS [58] and inhibited nitric oxide production in rat primary microglia
challenged with LPS [59]. PK11195, TTN and Ro5-4864 also downregulated TNF-α expression in
human and rodent microglia incubated with LPS [19,57]. LPS-challenged microglial cells (BV-2)
treated with XBD173 had significantly decreased expression of pro-inflammatory genes including
CCL-2, IL-6 and iNOS; XBD173-treated BV-2 cells also demonstrated reduced migratory capacity
and proliferation [20]. Endothelial activation is a clinical feature of vascular inflammation and is
characterized by the increased expression of cell-surface adhesion factors, e.g., VCAM-1 (vascular cell
adhesion molecule-1) [60]. The TSPO ligand midazolam caused inhibition of endothelial activation by
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lowering VCAM-1 expression in human umbilical vein endothelial cells challenged with TNF-α or the
phorbol 12-myristate 13-acetate (PMA) [28,31]. In the present study, for the first time, we demonstrated
that TSPO ligands promoted cholesterol efflux (Figure 1C) and upregulated expression of cholesterol
metabolism and trafficking genes in choroidal endothelial cells (Figure 2). The two ligands also
suppressed ROS production (Figure 5A), increased expression of antioxidant genes (Figure 5B,C) and
reduced secretion of pro-inflammatory cytokines including IL-1β, IL-6, TNF-α and VEGF (Figure 6).
TSPO ligands have shown protective effects in neurodegenerative animal models [61]. Previous
studies showed that Ro5-4864 reduced β-amyloid (Aβ) protein deposit and decreased gliosis in
the hippocampus of 3xTgAD mice. Aged 3xTgAD mice with Ro5-4864 treatment had decreased
anxiety and improved spontaneous alternation behaviour. Combinational treatment with Ro5-4864
and PK-11195 also lowered brain Aβ in nontransgenic young mice [62]. Treatment with Etifoxine
or XBD-173 resulted in improved clinical and neuropathological features in rodent multiple
sclerosis models through inhibition of inflammation, elevation of neurosteroids and prevention of
demyelination [57,63,64]. XBD-173 also showed protection of photoreceptors against light-induced
damage [65]. Both Etifoxine and XBD-173 have gone through clinical trials and showed therapeutic
effects in patients with anxiety [66,67]. Etifoxine is clinically available and used in more than 42 different
countries [67]. Our previous study [22] and current work have demonstrated a functional role of
Etifoxine and XBD-173 in RPE and choroidal endothelial cells, which are areas of primary dysfunction
in AMD. Consequently, Eitfoxine and XBD-173 may have therapeutic potential for AMD patients.
4. Materials and Methods
4.1. Cell Viability Assay
RF/6A (ATCC® CRL-1780™) cells were seeded at a density of 30,000 cells/ well in 96-well plates
(Greiner Bio One, Stonehouse, UK) with RPMI 1640 medium and cultured in a 5% CO2 incubator at
37 ◦C for 24 h. The cells were treated with different concentrations of Etifoxine and XBD173 (dissolved
in dimethyl sulfoxide, 0.1% DMSO) at 5, 7.5, 10, 15, 20, 25 or 30 µM for 24 h, with untreated cells
in media with 0.1% DMSO as controls. For the final 2 h of treatment incubation, the cells were
treated with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) solution (0.4 mg/mL
and 50 µL/well) (Sigma, Gillingham, UK) according to the manufacturer’s protocols. The optical
density (OD) was measured at 570 nm in a microplate reader (Epoch, Biotech, Winooski, VT, USA).
The untreated cell viability was taken to represent 100% cell viability. The percentage of cells viability
was calculated using the formula: % of viable cells = [(OD of untreated cells − OD of treated cells)/OD
of untreated cells] × 100.
4.2. Measurement of [3H]Cholesterol Efflux
Cholesterol efflux was measured from retinal choroidal endothelial cells that were cultured in
RPMI 1640 medium with fetal bovine serum (10%, v/v) and antibiotics (penicillin and streptomycin,
both 50 U/mL). The efflux protocol was adapted from our previous description [22]. Briefly, the RF/6A
cells were cultured in 12-well plates at the density of 2 × 105 cells/well. Next, the cells were labelled
with [3H] cholesterol in 0.1% BSA-added serum-free culture media for 24 h. Cells were exposed
to TSPO ligands (Etifoxine, 20 µM or XBD173, 25 µM) and different acceptors: ApoAI (10 µg/mL),
ApoE (10 µg/mL), HDL (20 µg/mL) and human serum (1%, v/v) for 24 h. After the incubation,
the labelled [3H]cholesterols from the media and from cells were counted on a scintillant counter.
Cholesterol efflux to each acceptor was calculated as % efflux = (disintegrations per minute (DPM)
media/DPM Media + DPM Cells) × 100.
4.3. Lipid Analysis
The incorporated [14C]acetate (1 µCi/mL) was measured from the lipid pools of phospholipids,
triglycerides, fatty acid, free cholesterol and cholesteryl ester, as previously reported [16]. In brief,
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the RF/6A cells were cultured on 12 well plates, seeded at a density of 250,000 cells/well. The cells
were labelled with [14C]acetate (1 µCi/mL). Next day, the cells were treated for 24 h with the
TSPO ligands (Etifoxine, 20 µM or XBD173, 25 µM in media containing 0.1% DMSO) and the
vehicle (media containing 0.1% DMSO). After 24 h, the cellular lipids were extracted by 3:2 (v/v)
hexanes: isopropanol. The lipid extracts were dried under nitrogen gas and dissolved in isopropanol.
The cellular lipids were separated by thin-layer chromatography (TLC) with two mobile phases:
phase-I was 60:30:5, (v/v/v) chloroform, methanol and water, while phase-II was 80:20:1.5, (v/v/v)
hexane, diethyl ether and acetic acid. The particular lipids were recognised by comigrated standards
and incorporation of radiolabel evaluated using scintillation counting.
4.4. Lipid Assays
The RF/6A cells were incubated with oxLDL (200 µg/mL) and treated with Etifoxine and
XBD173 in media containing 0.1% DMSO or vehicle control (media containing 0.1% DMSO) for
24 h. Following treatment, the mass of total cellular cholesterol and triglycerides were measured using,
respectively, the Amplex Red Cholesterol Assay Kit (Thermo Fisher Scientific, Waltham, MA, USA)
and EnzyChrom Triglyceride Assay Kit (BioAssay Systems, Hayward, CA, USA), according to the
manufacturer’s guidance.
4.5. Gene Expression
The RF/6A cells were seeded in 6 well plates at a density of 1 million cells per well. The following
day, the cells were treated with oxLDL and Etifoxine or XBD173 in media containing 0.1% DMSO at
the same time for 24 h. The choice of the 24 h window to detect gene expression is based our previous
studies [22] and a recent publication, which demonstrated that gene expression changes at 24 h in
PK11195-treated cells were functionally related to tumorigenesis and apoptosis [68]. Total RNA was
extracted using Tri Reagent (Sigma, UK) following the manufacturer’s instructions. The first-strand
cDNA was synthesised applying the High Capacity cDNA Reverse Transcription Kits and with the
RNAase inhibitor (Applied Biosystems, Birchwood, UK). The mRNA levels of the genes were then
quantified using qRT-PCR assay employing a Platinum Syber Green QAPCR Super Mix-UDG w/ROX
kit (Invitrogen, Inchinnam, UK). A 2−∆∆Ct formula was applied to quantify the relative expression of
the genes which were normalised to a housekeeping gene (β-actin). The sequences of these primers
used for gene expression are shown in Table 1.
Table 1. Primers used for qRT-PCR.
Gene Gene Bank Accession Number Primer Sequences (5′–3′) Forward Primer Sequences (5′–3′) Reverse
β-ACTIN NM_001033084.1 TCCACGAAACTACCTTCAACTC GTCATACTCCTGCTTGCTGAT
LXRα XM_015114352.1 CCCCATGACCGACTGATGTT CGGAGGCTCACCAGTTTCATT
ABCG1 XM_015132831.1 AAGGTGTCCTGCTACATCAT CAGTATCTCCTTGACCATCTC
ABCA1 XM_015117158.1 GAAGTACATCAGAACATGGGC GATCAAAGCCATGGCTGTAG
CYP46A1 XM_015144470.1 CCTTCTTCATTGCTGGTCACG TCCATCACTGTGAACGCCAAG
CYP27A1 NM_001194021.1 GGCAAGTACCCAGTACGG AGCAAATAGCTTCCAAGG
IL-1 β NM_001042756.1 ACCTGAGCTCGCCAGTGAAA GCCGGAAGCCCTCGTTGTAG
TNF-α NM_001047149.1 TCTCCTTCCTGCTCGTGGCA GGGTTTGCTACAACATGGGCTAC
IL6 XM_015133872.1 CCTTCCAAAGATGGCTGAAA CAGGGGTGGTTATTGCATCT
VEGFA NM_001278410.1 AAGGAGGAGGGCAGAATCAT ATCTGCATGGTGATGTTGGA
GPX1 NM_001159298.2 CTCTTCGAGAAGTGCGAGGT TCGATGTCAATGGTCTGGAA
SOD1 NM_001032804.1 AGGGCACCATCAATTTCGAG ACATTGCCCAGGTCTCCAAC
Catalase XM_001115625.3 CGCCTATGCAGCGAAGCTTA TTTGCGCATCTAGCACCGGA
4.6. Oil Red O (ORO) Staining
Oil Red O (Sigma, UK) was used to stain the RF/6A to detect neutral lipids. Cells were loaded with
oxLDL (200 µg/mL) along with Etifoxine and XBD173 in media containing 0.1% DMSO, or the controls
(media containing 0.1% DMSO), for 24 h. The cells were then stabilized with neutral buffered formalin
(10%, v/v) for 1 h at room temperature. The cells were washed with PBS twice and gently rinsed
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with 60% isopropanol. The cells were then stained with freshly prepared 6:4 ORO with de-ionised
water from the stock solution (0.5 g/mL). After 15 min of incubation, the cells were destained with
60% isopropanol briefly. The stained cells were examined under the EVOS® cell imaging systems
and data analysed using EVOS® FL software. Additionally, the lipid droplets were resuspended with
100% isopropanol and the absorbance measured in 96well plates at 520 nm. Total cellular protein
was extracted from the cells using 0.5 M NaOH and its concentration measured using the Bradford
protein assay.
4.7. Immunocytochemistry
The RF/6A cells were seeded on a coverslip. Next day, it was incubated with a marker of
functional mitochondria, MitoTracker® Deep Red FM (200 nM, Thermofisher Scientific, Inchinnam, UK)
in culture medium for 30 min to stain mitochondria. The cells were washed with PBS three times
and fixed with 4% paraformaldehyde (w/v) and then quickly rinsed with PBS. The slides were then
blocked with 2% sheep serum (v/v) and 2% BSA (w/v) in 1X PBS. Then, the slides were incubated
with anti-rabbit monoclonal TSPO primary antibody (Abcam ab109497, 1:200 dilutions) for one hour,
following which the slide was again blocked with 2% BSA (w/v) and then incubated with Alexa Fluor
488 secondary antibody. Subsequently, the slides were stained with DAPI (Abcam, Cambridge, UK)
to stain the nucleus. The images were acquired using LSM 800 confocal microscope (Carl Zeiss Ltd.,
Cambridge, UK).
4.8. Biochemical Assays
The RF/6A cells were seeded on six-well plates and treated as above. Catalase (CAT) and
Glutathione (GSSH/GSH) activities were observed in oxLDL-loaded cells treated with Etifoxine or
XBD173 in media containing 0.1% DMSO and with their control (media containing 0.1% DMSO) by
using OxiSelect Catalase Activity Assay Kit (Cell Biolabs, STA-341, San Diego, CA, USA) and the
OxiSelect total Glutathione Assay Kit (Cell Biolabs, STA-312, San Diego, CA, USA), following the
manufacturer’s guidelines. Similarly, malondialdehyde was quantified using the TBARS assay kit
(Cell Biolabs, STA-330, San Diego, CA, USA) according to the manufacturer’s protocol.
4.9. Measurement of Cytokines
The RF/6A cells were treated with oxLDL (200 mg/mL) and Etifoxine or XBD173 in media
containing 0.1% DMSO for 24 h or untreated as control (media containing 0.1% DMSO). After the
incubation, the medium was collected to quantify the levels of TNF-α, IL-1β, IL6 and IL8 by Peprotech
Enzyme-linked immunosorbent assay (ELISA) kits following the manufacturer’s protocols (Peprotech,
London, UK).
4.10. Statistical Analysis
All data were collected from three independent experiments and presented as mean ± SD.
The data were analysed by applying Prism 6 software using one-way ANOVA for unpaired and
two-way ANOVA for all pairwise comparisons, followed by the Bonferroni test (GraphPad Software
Inc., San Diego, CA, USA). p ≤ 0.05 was considered significant; * p ≤ 0.05, ** p < 0.01, *** p < 0.001 and
**** p < 0.0001.
5. Conclusions
The present study demonstrates that the TSPO ligands Etifoxine and XBD-173 enhance cholesterol
efflux, upregulate expression of cholesterol metabolism and transport genes, reduce oxLDL-induced
ROS production, and increased antioxidant capacity and suppress inflammation in choroidal
endothelial cells. TSPO ligands, particularly the clinically-used Etifoxine, have the potential to benefit
AMD patients.
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